



Hindustan Unilever Limited

Hindustan Unilever Limited
Unilever House
B D Sawant Marg
Chakala, Andheri East
Mumbai 400 099

Tel: +91 (22) 5043 3000
Web: www.hul.co.in
CIN: L15140MH1933PLC002030

13th March, 2020

To,

**Listing – Compliance Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Bandra-Kurla Complex, Bandra (East)
Mumbai 400 051**

This is with reference to your observation letter bearing reference no. NSE/LIST/19458 dated 15th February, 2019 regarding the Scheme of Amalgamation by way of merger by absorption among GlaxoSmithKline Consumer Healthcare Limited ("**Transferor Company**") and Hindustan Unilever Limited (the "**Company**") and their respective Shareholders and Creditors under section 230 to 232 of the Companies Act, 2013 (the "**Scheme**").

We further refer to our disclosures (i) dated November 06, 2019 wherein we had informed you that the Hon'ble National Company Law Tribunal, Mumbai Bench ("**Mumbai NCLT**"), had vide its Order dated 24th September, 2019, sanctioned the aforesaid Scheme; and (ii) dated February 26th, 2020 wherein we had informed you that the Scheme had received the sanction of the National Company Law Tribunal, Chandigarh Bench ("**Chandigarh NCLT**").

In this regard, we wish to inform you that the Transferor Company has now received the formal order as per Form CAA 7 of the Companies (Compromises, Arrangements and Amalgamation) Rules, 2016 issued by the Chandigarh NCLT.

In this regard we further wish to inform you that in accordance with the terms of the Scheme, a meeting of the Board of Directors of the Company is scheduled to be held on Wednesday, April 01, 2020, to take on record the sanction of the Scheme by the Mumbai NCLT and Chandigarh NCLT and to declare the Scheme effective from April 01, 2020.

Please take the same on record.

For Hindustan Unilever Limited

**Dev Bajpai
Executive Director (Legal and Corporate Affairs)
and Company Secretary
DIN : 00050516 / FCS: 3354**

